AI made execution free. Knowing first is the whole game now.
The advantage goes to whoever is first into the right conversations, most often. Fundz stacks those odds: more of the moments that create demand than anyone else catches, as they happen, matched to who you sell to, with the decision maker to call. Now it answers in Claude too: ask for today’s leads and who to reach, then write the note in the same window. Not a feed. Not a list you rent. A system for being first.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Kinoxis Therapeutics raises $6.75M in equity and $2.5M grant to advance dementia agitation treatments through clinical trials, with results expected in 2027.
Kinoxis Therapeutics, a dementia biotech company, has secured $6.75 million in equity funding led by Main Sequence Ventures, along with a $2.5 million government grant from Australia's Medical Research Future Fund. The total $9.25 million will fund clinical trials for drugs targeting agitation and pain associated with dementia. The company's lead candidate, KNX100, is in Phase 2 trials with initial results expected in mid-2027.
Company Information
Company
Kinoxis Therapeutics
Location
Melbourne, Victoria, Australia
About
Kinoxis Therapeutics is a dementia biotech company developing drugs for agitation, pain, and other symptoms associated with dementia. Founded in 2017 as a Sydney University spinout and now based in Melbourne, the company is advancing drug candidates through clinical trials, with KNX100 in Phase 2 testing for dementia-related agitation. The company has raised significant funding to support clinical development and plans to pursue partnerships for commercialization of treatments for brain-related conditions and pain.
Fundz sees it the moment Kinoxis Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MelbourneBiotechnologyHealth CareTherapeutics